Shares in Hims & Hers moved after the company chief financial officer completed preplanned option exercises and share sales under a Rule 10b5-1 trading plan, the SEC Form 4 filing shows.
The filing, dated April 20, 2026, reports the sales occurred on April 16 and April 17, 2026, and were effected pursuant to a trading plan adopted on May 21, 2025.
According to the Form 4, the CFO sold a total of 54,927 Class A shares, including 36,922 shares sold on April 16 at a weighted average price of $25.8964 per share.
The filing also shows 18,005 shares were sold on April 17 at a weighted average price of $27.8344 per share, and 6,184 stock options were exercised on April 17 at a $5.01 exercise price.
After the transactions and option exercise, the CFO directly holds 270,046 Class A shares and has indirect holdings of 7,853 shares held by the Oluyemi Okupe Separate Property Trust dated 9-1-2021, the filing states.
The Form 4 records 129,403 stock options still outstanding after the April 17 exercise, with an expiration date of February 23, 2032, and includes the signature of Kimberly Mather as attorney in fact for Oluyemi Okupe.
Market Momentum And Strategic Context
Hims & Hers stock has rallied sharply in recent weeks, with a reported 48 percent one week surge and intraday gains as much as 11 percent, according to coverage of market moves.
The rally followed an announcement that the Food and Drug Administration will hold a July meeting to consider easing peptide regulations, a shift publicly championed by Health Secretary Robert F. Kennedy Jr., the coverage notes.
The FDA previously restricted 19 peptides in 2023 and is now evaluating removal of 12 peptides from those restrictions, a change that could affect telehealth firms like Hims and their ability to offer peptide therapies.
Hims acquired a California peptide manufacturing facility in February 2025 and confirmed it is developing a peptide-based product line for a longevity specialty planned to launch this year, the reporting says.
The company’s prior growth included selling compounded GLP-1 products, which helped drive a reported 59 percent revenue increase to $2.35 billion in 2025, but also prompted regulatory and legal challenges with a major drugmaker.
Coverage notes an April 2025 partnership with Novo Nordisk collapsed amid accusations, and a later agreement had Hims prioritize distributing branded GLP-1s, with management guiding softer 19 percent revenue growth this year.
